Physician profile
Moeen Din
NPI 1598712259
$27,925.55
in general payments reported to CMS, 2019-2025
77 companies · $5,024 in 2025
The $5,024 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,617 · 2020: $2,919 · 2021: $4,097 · 2022: $3,663 · 2023: $4,727 · 2024: $4,878 · 2025: $5,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,396.64 |
| Education | $232.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,649.87 | 2021-2025 | Duopa, Qulipta, Ubrelvy |
| Ucb, INC. | $2,428.78 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,947.42 | 2019-2025 | |
| Biogen, INC. | $1,773.52 | 2019-2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $1,385.15 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Genzyme Corporation | $1,255.40 | 2019-2025 | |
| Amgen INC. | $969.37 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $911.01 | 2019-2025 | Ultomiris |
| Eisai INC. | $898.21 | 2019-2025 | |
| Argenx US, INC. | $860.39 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $796.80 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $755.01 | 2021-2025 | |
| Emd Serono, INC. | $675.34 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $653.19 | 2020-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $588.90 | 2019-2025 | Ingrezza, Ongentys |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moeen Din listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.